We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss
Read MoreHide Full Article
Shares of Mallinckrodt were down 13.5% after it reported mixed results for the third quarter of 2019.
Mallinckrodt’s stock has slumped 78.9% in the year so far compared with the industry’s decline of 1.6%.
The company reported adjusted earnings of $2.07 per share in the quarter, declining from the year-ago quarter’s $2.25 but easily beating the Zacks Consensus Estimate of $1.98.
Net sales in the quarter came in at $743.7 million, decreasing 7.1% year over year and falling short of the Zacks Consensus Estimate of $772.4 million.
Quarter in Detail
The company now operates two reportable segments aligned with the previously-announced separation — the Specialty Brands and the Specialty Generics.
Specialty Brands sales came in at $580.4 million, down 9.3% year over year.
Acthar, Mallinckrodt’s largest product, generated sales of $229.8 million, down 20.8% year over year primarily due to persistent reimbursement challenges impacting new and returning patients, and continued payer scrutiny on overall specialty pharmaceutical spending.
Inomax, the company’s second-largest product, generated sales of $136.8 million, up 2.7% year over year, driven by continued demand and significant utilization in multi-year, unlimited use contracts.
Ofirmev sales decreased 1.1% year over year to $86.1 million, due to lower demand and typical quarter-to-quarter order variability.
Sales of the Therakos immunology platform were $60.9 million, up 1.5% on growth in the United States.
Amitza net sales were $52.6 million, up 9.1% owing to consistent strong utilization in Japan, partially offset by an increasingly competitive landscape in the United States.
Specialty Generics sales amounted to $163.3 million, up 2.1% on share recapture across the business.
Adjusted selling, general and administrative expenses were $182 million, down from $205.2 million in the year-ago quarter. Research and development expenses increased to $103.1 million from $86.1 million, primarily owing to the $20-million up-front payment for collaboration with Silence Therapeutics concerning the RNAi technology platform for complement-mediated diseases.
Guidance Update
Earnings per share are now projected to be $8.50-$8.70, up from the previous guidance of $8.40-$8.70. The hospital business continues to perform well and the company expects the portfolio to see high-single-digit growth for the full year.
Pipeline Update
In September, Mallinckrodt reported positive top-line results for its phase III study demonstrating the benefit of StrataGraft regenerative skin tissue in patients with deep partial-thickness burns. The company plans to submit a BLA for StrataGraft tissue to the FDA in the first half of 2020.
Meanwhile, the CONFIRM study, which evaluated the efficacy and safety of pipeline candidate terlipressin in adults with HRS type I, met its primary endpoint. The company is planning to submit an NDA for the same to the FDA in early 2020.
Our Take
Mallinckrodt beat on earnings in the third quarter but missed sales estimates as Acthar continues to face reimbursement pressures because payers challenge longer duration prescriptions for certain indications.
Mallinckrodt public limited company Price and Consensus
Mallinckrodt is currently facing multiple challenges. The company was under the scanner for the sale and marketing of opioid drugs. Mallinckrodt and other industry players are accused of faulty marketing practices, which downplayed addiction risks from these drugs and spurred their consumption instead.
Nevertheless, it settled the initial cases in Ohio regarding the litigation.
Meanwhile, the Acthar label currently includes use in lupus patients and a positive readout from the phase IV trial could provide further information to appropriate patients regarding dosage and duration.
Zacks Rank & Key Picks
Mallinckrodt currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare space are FibroGen (FGEN - Free Report) , Lannett Inc. and Portola Pharmaceuticals . All stocks carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
FibroGen’s loss per share estimates have narrowed from 70 cents to 37 cents for 2019 in the past 90 days.
Portola’s loss per share estimates have narrowed from $3.83 to $3.77 for 2019 in the past 60 days.
Lannett’s earnings per share estimates have increased to $1.25 from $1.18 in the past 60 days.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss
Shares of Mallinckrodt were down 13.5% after it reported mixed results for the third quarter of 2019.
Mallinckrodt’s stock has slumped 78.9% in the year so far compared with the industry’s decline of 1.6%.
The company reported adjusted earnings of $2.07 per share in the quarter, declining from the year-ago quarter’s $2.25 but easily beating the Zacks Consensus Estimate of $1.98.
Net sales in the quarter came in at $743.7 million, decreasing 7.1% year over year and falling short of the Zacks Consensus Estimate of $772.4 million.
Quarter in Detail
The company now operates two reportable segments aligned with the previously-announced separation — the Specialty Brands and the Specialty Generics.
Specialty Brands sales came in at $580.4 million, down 9.3% year over year.
Acthar, Mallinckrodt’s largest product, generated sales of $229.8 million, down 20.8% year over year primarily due to persistent reimbursement challenges impacting new and returning patients, and continued payer scrutiny on overall specialty pharmaceutical spending.
Inomax, the company’s second-largest product, generated sales of $136.8 million, up 2.7% year over year, driven by continued demand and significant utilization in multi-year, unlimited use contracts.
Ofirmev sales decreased 1.1% year over year to $86.1 million, due to lower demand and typical quarter-to-quarter order variability.
Sales of the Therakos immunology platform were $60.9 million, up 1.5% on growth in the United States.
Amitza net sales were $52.6 million, up 9.1% owing to consistent strong utilization in Japan, partially offset by an increasingly competitive landscape in the United States.
Specialty Generics sales amounted to $163.3 million, up 2.1% on share recapture across the business.
Adjusted selling, general and administrative expenses were $182 million, down from $205.2 million in the year-ago quarter. Research and development expenses increased to $103.1 million from $86.1 million, primarily owing to the $20-million up-front payment for collaboration with Silence Therapeutics concerning the RNAi technology platform for complement-mediated diseases.
Guidance Update
Earnings per share are now projected to be $8.50-$8.70, up from the previous guidance of $8.40-$8.70. The hospital business continues to perform well and the company expects the portfolio to see high-single-digit growth for the full year.
Pipeline Update
In September, Mallinckrodt reported positive top-line results for its phase III study demonstrating the benefit of StrataGraft regenerative skin tissue in patients with deep partial-thickness burns. The company plans to submit a BLA for StrataGraft tissue to the FDA in the first half of 2020.
Meanwhile, the CONFIRM study, which evaluated the efficacy and safety of pipeline candidate terlipressin in adults with HRS type I, met its primary endpoint. The company is planning to submit an NDA for the same to the FDA in early 2020.
Our Take
Mallinckrodt beat on earnings in the third quarter but missed sales estimates as Acthar continues to face reimbursement pressures because payers challenge longer duration prescriptions for certain indications.
Mallinckrodt public limited company Price and Consensus
Mallinckrodt public limited company price-consensus-chart | Mallinckrodt public limited company Quote
Mallinckrodt is currently facing multiple challenges. The company was under the scanner for the sale and marketing of opioid drugs. Mallinckrodt and other industry players are accused of faulty marketing practices, which downplayed addiction risks from these drugs and spurred their consumption instead.
Nevertheless, it settled the initial cases in Ohio regarding the litigation.
Meanwhile, the Acthar label currently includes use in lupus patients and a positive readout from the phase IV trial could provide further information to appropriate patients regarding dosage and duration.
Zacks Rank & Key Picks
Mallinckrodt currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare space are FibroGen (FGEN - Free Report) , Lannett Inc. and Portola Pharmaceuticals . All stocks carry a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
FibroGen’s loss per share estimates have narrowed from 70 cents to 37 cents for 2019 in the past 90 days.
Portola’s loss per share estimates have narrowed from $3.83 to $3.77 for 2019 in the past 60 days.
Lannett’s earnings per share estimates have increased to $1.25 from $1.18 in the past 60 days.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>